Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)

J Gynecol Obstet Hum Reprod. 2019 Jun;48(6):379-386. doi: 10.1016/j.jogoh.2019.03.018. Epub 2019 Mar 29.

Abstract

Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).

Keywords: Chemotherapy; Guidelines; Ovarian cancer; Primary peritoneal cancer; Surgery; Tubal cancer.

Publication types

  • Practice Guideline

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bevacizumab / therapeutic use
  • Carboplatin / therapeutic use
  • Chemotherapy, Adjuvant
  • Fallopian Tube Neoplasms / drug therapy
  • Fallopian Tube Neoplasms / surgery*
  • Female
  • Fertility Preservation
  • France
  • Humans
  • Hyperthermia, Induced
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / surgery*
  • Paclitaxel / therapeutic use
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / surgery*

Substances

  • Bevacizumab
  • Carboplatin
  • Paclitaxel